Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Stations X's GenePool; DNAnexus' PaaS

Premium

Station X has launched GenePool, a cloud-based software application to manage, analyze, and communicate genomic and clinical information. Users can analyze sequence information from both DNA and RNA to identify biomarkers. The software has a web browser interface. Users can do analysis comparisons between tumor and normal genomes, analyses comparing responders and non-responders, and trio-based analyses for genetic diseases, among other applications.


DNAnexus has launched PaaS, or platform-as-a-service to enable clinical testing laboratories to move their analysis pipelines into the cloud using their own algorithms as well as industry tools and resources to create customized workflows. According to the company, the platform enables genomic research enterprises to expand their data analysis and storage infrastructure needs into the cloud and transform large capital expenditures into transparent operating expenses.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.